NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Accro Bioscience Inc.

Private
SuzhouHealthcare & Life Sciences

Last Round

Series C

May 18, 2026

Total Funding Raised

$50M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Accro Bioscience Inc. is a clinical-stage biotechnology company that pioneers the discovery, development, and commercialization of novel therapeutics for inflammatory and autoimmune diseases by targeting molecular mechanisms of regulatory cell death.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

oral therapeuticssmall molecule drugsregulated cell deathautoimmune disease therapeuticsRIPK2 inhibitorclinical-stage biotechUlcerative Colitisinflammatory disease therapeuticsdrug discoverybiotech licensingTYK2/JAK1 inhibitorplaque psoriasisIBD treatmentRIPK1 inhibitorGraft-versus-Host Disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Accro Bioscience Inc. Comps

Public and private peers based on sector, stage, and business model.

Accro Bioscience Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Accro Bioscience Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 18, 2026

Accro Bioscience Inc. Investors

Notable investors and investment history

Accro Bioscience Inc. investors
InvestorRounds
TCG CrossoverSeries C
Centurium CapitalSeries C
Oriza HoldingsSeries C
Yuanhe HoldingsSeries C
Shenzhen Capital GroupSeries C
OrbiMedSeries C
Cenova CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    $50M round led by OrbiMed.

  • Apr 7, 2026

    Monthly visitors increased 129% MoM.

Accro Bioscience Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Accro Bioscience Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Accro Bioscience Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range3
Year Founded2017
Last FundingMay 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.